The new chemical entity, compound 2, effectively reverses liver inflammation and fibrosis in a validated model of NASH and represents the first in class of a novel series of CysLT1R antagonists/GPBAR1 agonists. This evidence concerns the gene CYSLTR1 and metabolic dysfunction-associated steatohepatitis.